SPDR S&P Biotech (XBI) Shares Bought by HL Financial Services LLC

HL Financial Services LLC raised its position in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 10.3% during the second quarter, Holdings Channel reports. The firm owned 20,237 shares of the exchange traded fund’s stock after buying an additional 1,886 shares during the period. HL Financial Services LLC’s holdings in SPDR S&P Biotech were worth $1,562,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in XBI. Telemus Capital LLC purchased a new stake in SPDR S&P Biotech during the second quarter valued at $232,000. Stratos Wealth Partners LTD. increased its stake in SPDR S&P Biotech by 39.6% in the second quarter. Stratos Wealth Partners LTD. now owns 11,528 shares of the exchange traded fund’s stock valued at $890,000 after buying an additional 3,269 shares during the last quarter. Papp L Roy & Associates increased its stake in SPDR S&P Biotech by 3.1% in the second quarter. Papp L Roy & Associates now owns 187,538 shares of the exchange traded fund’s stock valued at $14,474,000 after buying an additional 5,648 shares during the last quarter. Weatherly Asset Management L. P. increased its stake in SPDR S&P Biotech by 4.5% in the second quarter. Weatherly Asset Management L. P. now owns 125,537 shares of the exchange traded fund’s stock valued at $9,689,000 after buying an additional 5,374 shares during the last quarter. Finally, David R. Rahn & Associates Inc. increased its stake in SPDR S&P Biotech by 51.7% in the second quarter. David R. Rahn & Associates Inc. now owns 38,631 shares of the exchange traded fund’s stock valued at $2,982,000 after buying an additional 13,170 shares during the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) opened at 77.26 on Thursday. The stock has a 50 day moving average price of $78.70 and a 200 day moving average price of $71.44. SPDR S&P Biotech has a 12-month low of $53.15 and a 12-month high of $82.38.

COPYRIGHT VIOLATION WARNING: “SPDR S&P Biotech (XBI) Shares Bought by HL Financial Services LLC” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2798720/spdr-sp-biotech-xbi-shares-bought-by-hl-financial-services-llc.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.